<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(1)</volume><submitter>Rai A</submitter><pubmed_abstract>Advancements in systems biology have resulted in the development of network pharmacology, leading to a paradigm shift from "one-target, one-drug" to "target-network, multi-component therapeutics". We employ a chimeric approach involving in-vivo assays, gene expression analysis, cheminformatics, and network biology to deduce the regulatory actions of a multi-constituent Ayurvedic concoction, Amalaki Rasayana (AR) in animal models for its effect in pressure-overload cardiac hypertrophy. The proteomics analysis of in-vivo assays for Aorta Constricted and Biologically Aged rat models identify proteins expressed under each condition. Network analysis mapping protein-protein interactions and synergistic actions of AR using multi-component networks reveal drug targets such as ACADM, COX4I1, COX6B1, HBB, MYH14, and SLC25A4, as potential pharmacological co-targets for cardiac hypertrophy. Further, five out of eighteen AR constituents potentially target these proteins. We propose a distinct prospective strategy for the discovery of network pharmacological therapies and repositioning of existing drug molecules for treating pressure-overload cardiac hypertrophy.</pubmed_abstract><journal>NPJ systems biology and applications</journal><pagination>11</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7884732</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Mapping drug-target interactions and synergy in multi-molecular therapeutics for pressure-overload cardiac hypertrophy.</pubmed_title><pmcid>PMC7884732</pmcid><pubmed_authors>Kumar V</pubmed_authors><pubmed_authors>Kartha CC</pubmed_authors><pubmed_authors>Jerath G</pubmed_authors><pubmed_authors>Rai A</pubmed_authors><pubmed_authors>Ramakrishnan V</pubmed_authors></additional><is_claimable>false</is_claimable><name>Mapping drug-target interactions and synergy in multi-molecular therapeutics for pressure-overload cardiac hypertrophy.</name><description>Advancements in systems biology have resulted in the development of network pharmacology, leading to a paradigm shift from "one-target, one-drug" to "target-network, multi-component therapeutics". We employ a chimeric approach involving in-vivo assays, gene expression analysis, cheminformatics, and network biology to deduce the regulatory actions of a multi-constituent Ayurvedic concoction, Amalaki Rasayana (AR) in animal models for its effect in pressure-overload cardiac hypertrophy. The proteomics analysis of in-vivo assays for Aorta Constricted and Biologically Aged rat models identify proteins expressed under each condition. Network analysis mapping protein-protein interactions and synergistic actions of AR using multi-component networks reveal drug targets such as ACADM, COX4I1, COX6B1, HBB, MYH14, and SLC25A4, as potential pharmacological co-targets for cardiac hypertrophy. Further, five out of eighteen AR constituents potentially target these proteins. We propose a distinct prospective strategy for the discovery of network pharmacological therapies and repositioning of existing drug molecules for treating pressure-overload cardiac hypertrophy.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Feb</publication><modification>2024-11-08T20:30:24.686Z</modification><creation>2021-02-28T08:15:30Z</creation></dates><accession>S-EPMC7884732</accession><cross_references><pubmed>33589646</pubmed><doi>10.1038/s41540-021-00171-z</doi></cross_references></HashMap>